4WO Stock Chart & Stats
€0.66
>-€0.01(-1.71%)
At close: 4:00 PM EST
€0.66
>-€0.01(-1.71%)
Day’s Range― - ―
52-Week Range€0.39 - €0.78
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€360.27M
Enterprise Value€2.45K
Total Cash (Recent Filing)€766.57M
Total Debt (Recent Filing)€652.57M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding676,961,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)1.95
Price to Sales (P/S)5.04
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.14Price Target Upside72.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€101.25M
Bulls Say, Bears Say
Bulls Say
Revenue ExpansionThe company has achieved meaningful revenue scale-up over several years, indicating growing adoption of its interventional medical-device portfolio. Continued expansion can broaden procedure volumes and hospital reach, creating a foundation for operating leverage if commercialization remains effective.
Strong Gross MarginA gross margin near 67% provides substantial economic value from each unit sold and can support investment in product development, regulatory expansion, and commercialization. This margin profile also offers potential operating leverage if revenue growth continues and fixed costs are better absorbed.
Manageable LeverageLow debt relative to equity reduces balance-sheet leverage and limits the burden of mandatory financing costs. Sizable capitalization gives Peijia Medical more flexibility to fund product development and market expansion while absorbing ongoing losses, although earnings recovery remains important.
Bears Say
Persistent Operating LossesPersistent operating and net losses show that revenue growth has not yet translated into a profitable business model. The negative margin limits internally generated funding, may require continued cost discipline, and leaves future earnings power dependent on achieving better operating leverage.
Negative Cash GenerationOngoing operating cash outflows and materially negative free cash flow mean the business is consuming cash even as revenue scales. Until cash conversion improves, Peijia Medical may have less flexibility to fund development internally and greater dependence on external financing.
Negative Returns On EquityNegative ROE indicates that the substantial equity base is not yet producing positive returns for the business. If losses persist, capital efficiency remains weak and accumulated deficits could gradually reduce the capacity to reinvest productively or support expansion without improved profitability.
Peijia Medical Ltd. News
4WO FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was €0.39 and its highest was €0.78 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is €360.27M.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 193 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Aug 21, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Undervalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 676,961,900 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -1.923%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in DE:4WO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
4WO Stock 12 Month Forecast
Average Price Target
€1.14
▲(72.47% Upside)
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―